Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
METABOLYX: Secukinumab With or Without Lifestyle Intervention in Psoriasis and Metabolic Syndrome
NCT03440736Phase 4Completed
- Sponsor
- Novartis
- Start
- Feb 2018
- Primary completion
- Nov 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 4 trial of secukinumab in psoriasis, sponsored by Novartis. Started Feb 2018; status: completed.
02
Drugs
secukinumab
03
Conditions
psoriasis
Beyond the preview
Go deeper on NCT03440736.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03440736.